Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The Effect of Theophylline in Patients With Allergic Rhinitis
NCT01132781Phase 2Completed
- Sponsor
- University of East Anglia
- Start
- May 2010
- Primary completion
- Jun 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of theophylline in allergic rhinitis (AR) and chronic rhinosinusitis (CRS) (2 arms), sponsored by University of East Anglia. Primary endpoint: Total Nasal Symptom Score at 18 weeks. Started May 2010; status: completed.
02
Drugs
theophylline
03
Conditions
allergic rhinitis (AR)chronic rhinosinusitis (CRS)
Beyond the preview
Go deeper on NCT01132781.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01132781.